Verastem, Inc. (LON:0LOV)

Market Cap	796.22M +94.5%
Revenue (ttm)	75.55M +649.7%
Net Income	-134.76M
EPS	-1.46
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	513
Open	8.75
Previous Close	8.75
Day's Range	8.50 - 8.76
52-Week Range	3.44 - 10.67
Beta	0.46
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Verastem

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 102
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LOV

Financial Performance

In 2025, Verastem's revenue was $30.91 million, an increase of 209.14% compared to the previous year's $10.00 million. Losses were -$209.47 million, 60.3% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error